Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

European Innovation Council · Running

STIMULUS Speckle Technology and Digital Biomarkers of Microvascular Function for Monitoring Cardiovascular Diseases

Coordinator
Turun Yliopisto, Finland
Runs
1 October 2023 to 30 September 2027
Status
Running
EU funding
€4.6m
Total cost
€4.6m
Partners
7 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101115492

What the project is doing

In the project's own words, from its summary on CORDIS.

Over 60 million people in the EU live with cardiovascular diseases (CVDs), at an annual economic cost of +210B€. Despite being largely preventable, CVDs cause more than 18.5 million deaths every year. To combat this, we develop new instruments for assessing adverse changes in microcirculatory status linked to hypertension, chronic kidney disease (CKD) and heart failure (HF), leading to earlier detection of CVDs. The instruments are developed and validated in clinical trials.

We integrate two state-of-the-art technologies leading to a novel innovation, 3D speckle tissue monitoring. In addition, we demonstrate a direct use-case for unobtrusive monitoring in a smart-toilet application. Global remote patient monitoring (RPM) systems market is expected to surpass 5 B$ by 2030 with CAGR of 20%. The demand for the RPM systems is rapidly growing among the old age population. Monitoring innovations targeting this group can reduce hospitalization and costly chronic conditions.

Furthermore, the technology is closely linked to wearable remote monitoring. The global wearable technology market is expected to grow to 392 B$ by 2030 with CAGR of 13.9%. The opportunity is significant as the number of wearable users currently exceeds 1 billion globally and the developed technology targets similar markets. We currently estimate that with the new instrument and digital biomarkers we can reduce the healthcare burden by over 30% by preventing CVDs.

Additionally, we are aiming to identify citizens at risk of developing hypertension, CKD and/or HF and by timely intervention, we expect to reduce indirect healthcare costs by over 20%. In conclusion, our solution will integrate two existing state-of-the-art methods and provide clearly new monitoring techniques to assess the microcirculatory status, revealing early signs of CVDs. We will provide an innovative solution to emerging digital unobtrusive health markets while helping the over 60 million Europeans suffering from CVDs.

Topics

Who is involved

OrganisationCityCountryRole
Turun YliopistoTurkuFinlandCoordinator
Karlsruher Institut Fuer TechnologieKarlsruheGermanyParticipant
Region Nordjylland (north Denmark Region)AalborgDenmarkParticipant
Ethnicon Metsovion PolytechnionAthinaGreeceParticipant
Suomen Sydanliito RyHelsinkiFinlandAssociatedpartner
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Stichting IMEC NederlandEindhovenNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI